Akarna Therapeutics Announces Formation of Clinical Advisory Board

Akarna Therapeutics Announces Formation of Clinical Advisory Board

Recruits key opinion leaders to help guide clinical development of its FXR program

SAN DIEGO, USA, April 11, 2016 – Akarna Therapeutics Ltd., a privately held biopharmaceutical company, today announced the formation of its Clinical Advisory Board.

Members of the Akarna Clinical Advisory Board include:

Ariel Feldstein, M.D.
Chief, Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of California, San Diego, CA

Scott Friedman, M.D.
Chief, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY

John Kastelein, M.D., Ph.D.
Professor of Medicine, AMC, University of Amsterdam, Amsterdam, The Netherlands

Paul Pockros, M.D.
Director, Liver Disease Center, Scripps Clinic; Director of Clinical Research, Scripps Translational Science Institute, La Jolla, CA

Arun Sanyal, M.D.
Chair, Division of Gastroenterology, Hepatology and Nutrition, School of Medicine, Virginia Commonwealth University, Richmond, VA

Simeon Taylor, M.D., Ph.D.
University of Maryland School of Medicine, Baltimore, MD

 

“We are honored to have these accomplished thought leaders join our advisory board,” said Raju Mohan, Ph.D., Chief Executive Officer of Akarna. “They are all leading experts in their field and the broad range of experience and expertise that they bring in liver disease, metabolic syndrome and cardiovascular disease will be invaluable as we progress our lead non-bile acid FXR agonist through human proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies.”

“I’m delighted to join Akarna’s advisory board along with other distinguished key opinion leaders,” stated Dr. Scott Friedman, Chief, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai in New York and the chair of Akarna’s CAB. “I look forward to providing guidance to the Akarna team as they move their lead product candidate into the clinic.”

 

About Akarna Therapeutics

Akarna Therapeutics is a privately held biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases for which there are no approved treatments. Akarna’s lead program is a potential best-in-class FXR agonist for the treatment of NASH. For more information about our Clinical Advisory Board and Akarna, please visit us at www.akarna.com.

 

Akarna Therapeutics Contact:
Raju Mohan, PhD
P: +1 858-945-6156
E: rmohan@akarna.com

Media Contact:
Mike Beyer
Sam Brown Inc.
P: +1 312-961-2502
E: mikebeyer@sambrown.com

 

To download this press release, click here